Truist analyst Tobey Sommer lowered the firm’s price target on Insperity (NSP) to $70 from $82 and keeps a Hold rating on the shares after its Q1 earnings miss and below-consensus guide. The firm is citing deteriorating SMB sentiment and risks of further healthcare issues, along with higher healthcare utilization, the analyst tells investors in a research note.

Protect Your Portfolio Against Market Uncertainty

Discover companies with rock-solid fundamentals in  TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty,  delivered straight to your inbox.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on NSP:

Disclaimer & DisclosureReport an Issue

Insperity Reports Q1 2025 Financial Results Insperity falls -14.2% Insperity falls -18.2% Insperity cuts FY25 adjusted EPS view to $2.23-$3.28 from $3.10-$3.95 Insperity reports Q1 adjusted EPS $1.57, consensus $2.02

View Comments